Arcturus Therapeutics is no longer the binary ARCT-032 cystic fibrosis story the Street has been pricing for the last two years. With the August termination of the CSL Seqirus collaboration, the company has recaptured global rights to KOSTAIVE and the rest of the sa-mRNA vaccine portfolio, taken a cash settlement, and been released from a sizable R&D credit liability. In the same week, Arcturus signed a strategic agreement with Thermo Fisher Scientific under which Thermo Fisher has agreed to provide up to $40 million of qualifying Phase 3 clinical manufacturing services for the lead program. The combined effect is a meaningful rebalancing of the equity story: the company now owns its vaccine optionality, has a deep-pocketed partner underwriting the most expensive part of its lead rare-disease program, and reports a balance sheet that management says supports operations into late 2028.
The Q2 print reads as a quarter of transition rather than operational weakness. Total revenue collapsed versus the year-ago quarter, but the comparison is artificially inflated by CSL milestone recognition that is now winding down. Research and development expense fell sharply, driven by lower clinical and manufacturing spend as the LUNAR-COVID, BARDA, and LUNAR-CF programs wind through their planned cadence. Net loss widened, almost entirely on the loss of CSL revenue and lower interest income, with operating loss moving in tandem. The optics are ugly in a single-quarter read, but the underlying expense base tells a more disciplined story and the company is no longer a one-partner revenue story.
The trade is straightforward to articulate. Arcturus is a roughly $190 million cash, two-pipeline-asset mRNA platform that has, in the span of two weeks, traded one revenue partner for a manufacturing partner and a sizable in-kind offset. We see the equity as a binary on the lead program's Phase 2 readout expected around the late-2026 Phase 3 go/no-go decision, with KOSTAIVE optionality now sitting in shareholder hands rather than in CSL's royalty stream. The risk profile has not changed in kind; it has simply been re-segmented. Bears focus on the absence of recurring collaboration revenue; we see the termination as a one-time reset that converts deferred revenue into Q3 recognition and swaps a royalty obligation for a royalty stream in the other direction.